Top

Published in:

Open Access 01-06-2010 | Review Article

Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development

Author: Paul A. Lapchak

Published in: Translational Stroke Research | Issue 2/2010

Abstract

Alteplase (tissue plasminogen activator, tPA) is currently the only FDA-approved treatment that can be given to acute ischemic stroke (AIS) patients if patients present within 3 h of an ischemic stroke. After 14 years of alteplase clinical research, evidence now suggests that the therapeutic treatment window can be expanded 4.5 h, but this is not formally approved by the FDA. Even though there remains a significant risk of intracerebral hemorrhage associated with alteplase administration, there is an increased chance of favorable outcome with tPA treatment. Over the last 30 years, the use of preclinical models has assisted with the search for new effective treatments for stroke, but there has been difficulty with the translation of efficacy from animals to humans. Current research focuses on the development of new and potentially useful thrombolytics, neuroprotective agents, and devices which are also being tested for efficacy in preclinical and clinical trials. One model in particular, the rabbit small clot embolic stroke model (RSCEM) which was developed to test tPA for efficacy, remains the only preclinical model used to gain FDA approval of a therapeutic for stroke. Correlative analyses from existing preclinical translational studies and clinical trials indicate that there is a therapeutic window ratio (ARR) of 2.43-3 between the RSCEM and AIS patients. In conclusion, the RSCEM can be used as an effective translational tool to gauge the clinical potential of new treatments.

Ingall T (2004) Stroke-incidence, mortality, morbidity and risk. J Insur Med 36(2):143–152PubMed

Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al (2009) Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3):480–486CrossRefPubMed

Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO (2000) Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 31(5):1062–1068PubMed

Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO (1999) Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 30(12):2513–2516PubMed

Lapchak PA (2002) Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs 11(11):1623–1632CrossRefPubMed

Lapchak PA, Araujo DM (2007) Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs 12(1):97–112CrossRefPubMed

Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22(9):391–397CrossRefPubMed

Michel P, Bogousslavsky J (2005) Penumbra is brain: no excuse not to perfuse. Ann Neurol 58(5):661–663CrossRefPubMed

Moustafa RR, Baron JC (2006) Imaging the penumbra in acute stroke. Curr Atheroscler Rep 8(4):281–289CrossRefPubMed

10.

Fisher M (2004) The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc Dis 17:1–6CrossRefPubMed

11.

Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, Hacke W (2001) Thrombolytic therapy for ischemic stroke—a review. Part II—Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging. Crit Care Med 29(9):1819–1825CrossRefPubMed

12.

Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, Hacke W (2001) Thrombolytic therapy for ischemic stroke—a review. Part I—Intravenous thrombolysis. Crit Care Med 29(9):1812–1818CrossRefPubMed

13.

Verstraete M (1999) Newer thrombolytic agents. Ann Acad Med Singapore 28(3):424–433PubMed

14.

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359(13):1317–1329CrossRefPubMed

15.

Lansberg MG, Bluhmki E, Thijs VN (2009) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 40(7):2438–2441CrossRefPubMed

16.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333(24):1581–1587CrossRef

17.

No authors listed (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30(12):2752–2758

18.

Ginsberg MD (2007) Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke 38(6):1967–1972CrossRefPubMed

19.

Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM et al (2007) NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357(6):562–571CrossRefPubMed

20.

Bailey EL, McCulloch J, Sudlow C, Wardlaw JM (2009) Potential animal models of lacunar stroke: a systematic review. Stroke 40(6):e451–e458CrossRefPubMed

21.

Prieto-Arribas R, Moreno-Gutierrez A, Simal-Hernandez P, Pascual-Garvi JM, Matias-Guiu J, Roda JM et al (2008) Experimental models of cerebral ischemia. Rev Neurol 47(8):414–426PubMed

22.

Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL et al (2008) Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab 28(1):217–219CrossRefPubMed

23.

Durukan A, Tatlisumak T (2007) Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 87(1):179–197CrossRefPubMed

24.

Hua R, Walz W (2006) The need for animal models in small-vessel brain disease. Crit Rev Neurobiol 18(1–2):5–11PubMed

25.

Carmichael ST (2005) Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2(3):396–409CrossRefPubMed

26.

Fukuda S, del Zoppo GJ (2003) Models of focal cerebral ischemia in the nonhuman primate. ILAR J 44(2):96–104PubMed

27.

Traystman RJ (2003) Animal models of focal and global cerebral ischemia. ILAR J 44(2):85–95PubMed

28.

Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T et al (1999) Underlying structure of the national institutes of health stroke scale: results of a factor analysis. Stroke 30:2347PubMed

29.

Lyden P, Raman R, Liu L, Grotta J, Broderick J, Olson S et al (2005) NIHSS training and certification using a new digital video disk is reliable. Stroke 36(11):2446–2449CrossRefPubMed

30.

Sulter G, Steen C, De Keyser J (1999) Use of the Barthel Index and modified Rankin Scale in acute stroke trials. Stroke 30:1538PubMed

31.

Wilson JT, Hareendran A, Grant M, Baird T, Schultz UGR, Muir KW et al (2002) Improving the assessment of outcomes in strokes. Stroke 33:2243CrossRefPubMed

32.

Young FB, Lees KR, Weir CJ (2003) Strengthening acute stroke trials through optimal use of disability end points. Stroke 34(11):2676–2680CrossRefPubMed

33.

Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA (1985) Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230(4731):1289CrossRefPubMed

34.

Phillips DA, Davis MA, Fisher M (1988) Selective embolization and clot dissolution with tPA in the internal carotid artery circulation of the rabbit. AJNR Am J Neuroradiol 9(5):899–902PubMed

35.

Phillips DA, Fisher M, Smith TW, Davis MA (1988) The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. Ann Neurol 23(4):391–394CrossRefPubMed

36.

Chehrazi BB, Seibert JA, Kissel P, Hein L, Brock JM (1989) Evaluation of recombinant tissue plasminogen activator in embolic stroke. Neurosurgery 24(3):355–360CrossRefPubMed

37.

Gross CE, Raymond SJ, Howard DB, Bednar MM (1995) Delayed tissue-plasminogen activator therapy in a rabbit model of thromboembolic stroke. Neurosurgery 36(6):1172–1177CrossRefPubMed

38.

Lapchak PA (2009) Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model. Brain Res 1294:211–217CrossRefPubMed

39.

Lapchak PA, De Taboada L (2010) Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5′-triphosphate (ATP) content following embolic strokes in rabbits. Brain Res 1306:100–105CrossRefPubMed

40.

Lapchak PA, Streeter J, De Taboada L (2010) Transcranial near infrared laser therapy (NILT) to treat acute ischemic stroke: a review of efficacy, safety and possible mechanism of action derived from rabbit embolic stroke studies. Proc SPIE 7552:75520RCrossRef

41.

Matchett GA, Allard MW, Martin RD, Zhang JH (2009) Neuroprotective effect of volatile anesthetic agents: molecular mechanisms. Neurol Res 31(2):128–134CrossRefPubMed

42.

Kawaguchi M, Furuya H, Patel PM (2005) Neuroprotective effects of anesthetic agents. J Anesth 19(2):150–156CrossRefPubMed

43.

Koerner IP, Brambrink AM (2006) Brain protection by anesthetic agents. Curr Opin Anaesthesiol 19(5):481–486CrossRefPubMed

44.

Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA (2002) Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33(5):1411–1415CrossRefPubMed

45.

Lapchak PA, Araujo DM, Zivin JA (2004) Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 185(1):154–159CrossRefPubMed

46.

Lapchak PA, Wei J, Zivin JA (2004) Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke 35(8):1985–1988CrossRefPubMed

47.

Lapchak PA, Zivin JA (2009) The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol 215(1):95–100CrossRefPubMed

48.

Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ et al (2001) Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32(12):2926–2931CrossRefPubMed

49.

Asahi M, Asahi K, Wang X, Lo EH (2000) Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 20(3):452–457CrossRefPubMed

50.

Kano T, Harada T, Katayama Y (2005) Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. Neurol Res 27(5):499–502CrossRefPubMed

51.

Kano T, Katayama Y, Tejima E, Lo EH (2000) Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. Brain Res 854(1–2):245–248CrossRefPubMed

52.

Meden P, Overgaard K, Pedersen H, Boysen G (1994) Effect of hypothermia and delayed thrombolysis in a rat embolic stroke model. Acta Neurol Scand 90(2):91–98CrossRefPubMed

53.

Overgaard K, Sereghy T, Pedersen H, Boysen G (1994) Effect of delayed thrombolysis with rt-PA in a rat embolic stroke model. J Cereb Blood Flow Metab 14(3):472–477PubMed

54.

Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA (2000) Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. Jama 283(9):1145–1150CrossRefPubMed

55.

Alberts MJ (1998) tPA in acute ischemic stroke: United States experience and issues for the future. Neurology 51(3 Suppl 3):S53–S55PubMed

56.

Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M et al (2000) Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke 31(8):1812–1816PubMed

57.

Clark WM, Albers GW, Madden KP, Hamilton S (2000) The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 31(4):811–816PubMed

58.

Grotta JC, Alexandrov AV (1998) tPA-associated reperfusion after acute stroke demonstrated by SPECT. Stroke 29(2):429–432PubMed

59.

Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB et al (2001) Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 58(12):2009–2013CrossRefPubMed

60.

Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R et al (1999) Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53(7):S3–S14PubMed

61.

Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R et al (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). Jama 274(13):1017–1025CrossRefPubMed

62.

Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC et al (2000) Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology 55(11):1649–1655PubMed

63.

Zunker P, Schick A, Padro T, Kienast J, Phillips A, Ringelstein EB (1999) Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology. Neurol Res 21(8):727–732PubMed

64.

Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC (2003) Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtyp really matter? Neurology 61:71–75PubMed

65.

del Zoppo G (1988) Thrombolytic therapy in cerebrovascular disease. Curr Concepts Cerebrovasc Dis 23:7

66.

Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR (2003) Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 34(9):2228–2233CrossRefPubMed

67.

Marshall JW, Duffin KJ, Green AR, Ridley RM (2001) NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32(1):190–198PubMed

68.

Marshall JW, Green AR, Ridley RM (2003) Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. Brain Res 972(1–2):119–126CrossRefPubMed

69.

Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM (2001) Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology 40(3):433–439CrossRefPubMed

70.

Sydserff SG, Borelli AR, Green AR, Cross AJ (2002) Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 135(1):103–112CrossRefPubMed

71.

Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM (2001) NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 909(1–2):46–50CrossRefPubMed

72.

Lapchak PA (2002) NXY-059. Centaur. Curr Opin Investig Drugs 3(12):1758–1762PubMed

73.

Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK (1999) Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 19(7):778–787CrossRefPubMed

74.

Green AR, Lanbeck-Vallen K, Ashwood T, Lundquist S, Lindström Böö E, Jonasson H et al (2006) Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia. Brain Res 1072(1):224–226CrossRefPubMed

75.

Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR (2009) Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol 157(7):1157–1171CrossRefPubMed

76.

Lapchak PA, Song D, Wei J, Zivin JA (2004) Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol 188(2):279–285CrossRefPubMed

77.

Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC et al (2006) NXY-059 for acute ischemic stroke. N Engl J Med 354(6):588–600CrossRefPubMed

78.

Watanabe T, Tahara M, Todo S (2008) The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther 26(2):101–114CrossRefPubMed

79.

Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N (2006) Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 12(1):9–20 (spring)CrossRefPubMed

80.

Toyoda K, Fujii K, Kamouchi M, Nakane H, Arihiro S, Okada Y et al (2004) Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci 221(1–2):11–17CrossRefPubMed

81.

Mishina M, Komaba Y, Kobayashi S, Tanaka N, Kominami S, Fukuchi T et al (2005) Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction. Neurol Med Chir (Tokyo) 45(7):344–348, discussion 8CrossRef

82.

Inatomi Y, Takita T, Yonehara T, Fujioka S, Hashimoto Y, Hirano T et al (2006) Efficacy of edaravone in cardioembolic stroke. Intern Med 45(5):253–257CrossRefPubMed

83.

EAISG (2003) Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15(3):222–229CrossRef

84.

Suda S, Igarashi H, Arai Y, Andou J, Chishiki T, Katayama Y (2007) Effect of edaravone, a free radical scavenger, on ischemic cerebral edema assessed by magnetic resonance imaging. Neurol Med Chir (Tokyo) 47(5):197–201, discussion 2CrossRef

85.

Yoshifumi T (ed) (2007) Benefits of pre-treatmetn with edaravone in tPA intravenous therapy for acute cerebral infarction. XXIIIrd International Symposium on Cerebral Blood Flow (abstract)

86.

Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM et al (2008) NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II trials. Stroke 39(6):1751–1758CrossRefPubMed

87.

Sinha M, Anuradha H, Juyal R, Shukla R, Garg R, Kar A (2009) Edaravone in acute ischemic stroke, an Indian experience. Neurology Asia 14:7–10

88.

Hishida A (2007) Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol 11(4):292–296CrossRefPubMed

89.

Detaboada L, Ilic S, Leichliter-Martha S, Oron U, Oron A, Streeter J (2006) Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke. Lasers Surg Med 38(1):70–73CrossRefPubMed

90.

Ilic S, Leichliter S, Streeter J, Oron A, DeTaboada L, Oron U (2006) Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain. Photomed Laser Surg 24(4):458–466CrossRefPubMed

91.

Oron A, Oron U, Chen J, Eilam A, Zhang C, Sadeh M et al (2006) Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. Stroke 37(10):2620–2624CrossRefPubMed

92.

Lapchak PA, Salgado KF, Chao CH, Zivin JA (2007) Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: an extended therapeutic window study using continuous and pulse frequency delivery modes. Neuroscience 148(4):907–914CrossRefPubMed

93.

Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, Andersson B, Perez J, Caparo C, Ilic S, Oron U (2007) Infrared laser therapy for ischemic stroke—a new treatment strategy: results of the NeuorThera Effectiveness and Safety Trial-1 (NEST-1). Stroke 38:1843–1849CrossRefPubMed

94.

Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T et al (2009) Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke 40(4):1359–1364CrossRefPubMed

95.

Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr (2009) Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke 40:2945–2948CrossRefPubMed

96.

Kitagawa Y (2006) Edaravone in acute ischemic stroke. Intern Med 45(5):225–226CrossRefPubMed

97.

Karbowski J (2007) Global and regional brain metabolic scaling and its functional consequences. BMC Biol 5:18CrossRefPubMed

98.

Gelineo S (1964) Organ systems in adaptation: the temperature regulating system. In: Dill DB (ed) Adaptation to the environment. Handbook of physiological science, section 4. Williams & Wilkins, Baltimore, pp 259–282

99.

Durnin JVGA (1981) Basal metabolic rate in man. FAO/WHO/UNU Expert Consultation on Energy and Protein Requirements

100.

Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P et al (2002) Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106(6):740–745PubMed

101.

Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M (2009) Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model. J Cereb Blood Flow Metab 29(1):119–129CrossRefPubMed

Title: Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development
Author: Paul A. Lapchak
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Translational Stroke Research / Issue 2/2010
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-010-0018-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Inflammation After Stroke: Mechanisms and Therapeutic Approaches

Administration of a Sigma Receptor Agonist Delays MCAO-Induced Neurodegeneration and White Matter Injury

Magnesium Sulfate Treatment Improves Outcome in Patients with Subarachnoid Hemorrhage: A Meta-analysis Study

Association Between Changes in Weight and Cerebral Arteries in Rats

Ccm1 Assures Microvascular Integrity During Angiogenesis

Implications of Immune System in Stroke for Novel Therapeutic Approaches